CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-01 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise · Restricted Share Unit 10b5-1 | −2,497 | 4,995 | ||
| 2024-09-01 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise · Restricted Share Unit 10b5-1 | −1,624 | 4,872 | ||
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +4,089 | 22,480 | ||
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Shares withheld for taxes 10b5-1 | −1,393 | $26.74 | $37K | 21,087 |
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Grant or award · Restricted Share Unit 10b5-1 | +6,962 | 6,962 | ||
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Grant or award · Share Option 10b5-1 | +36,100 | 36,100 | ||
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Option exercise · Restricted Share Unit 10b5-1 | −2,477 | 4,954 | ||
| 2024-09-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Option exercise · Restricted Share Unit 10b5-1 | −1,612 | 4,833 | ||
| 2024-08-27 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +10,000 | $1.59 | $16K | 137,411 |
| 2024-08-27 | Tessari Eben CHIEF OPERATING OFFICER | Sale 10b5-1 | −17,500 | $26.91 | $471K | 119,911 |
| 2024-08-27 | Tessari Eben CHIEF OPERATING OFFICER | Option exercise · Share Option 10b5-1 | −10,000 | 46,017 | ||
| 2024-07-23 | Patel Sanj K CHAIRMAN & CEO | Option exercise 10b5-1 | +136,124 | $1.59 | $216K | 199,136 |
| 2024-07-23 | Patel Sanj K CHAIRMAN & CEO | Sale 10b5-1 | −23,075 | $23.25 | $536K | 176,061 |
| 2024-07-23 | Patel Sanj K CHAIRMAN & CEO | Sale 10b5-1 | −50,000 | $25.05 | $1.3M | 126,061 |
| 2024-07-23 | Patel Sanj K CHAIRMAN & CEO | Sale 10b5-1 | −63,049 | $27.01 | $1.7M | 63,012 |
| 2024-07-23 | Patel Sanj K CHAIRMAN & CEO | Option exercise · Share Option 10b5-1 | −136,124 | 189,147 | ||
| 2024-07-23 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +24,248 | $11.10 | $269K | 43,501 |
| 2024-07-23 | Ragosa Mark CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −24,248 | $24.79 | $601K | 19,253 |
| 2024-07-23 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise · Share Option 10b5-1 | −24,248 | 40,412 | ||
| 2024-07-23 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +22,000 | $1.86 | $41K | 69,803 |
Page 49 of 74 · 1,467 trades